What is William Blair's Forecast for Biogen Q3 Earnings?

Biogen Inc. (NASDAQ:BIIB - Free Report) - Analysts at William Blair issued their Q3 2025 earnings per share (EPS) estimates for Biogen in a research note issued on Tuesday, July 15th. William Blair analyst M. Minter forecasts that the biotechnology company will earn $4.03 per share for the quarter. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. William Blair also issued estimates for Biogen's Q4 2025 earnings at $3.58 EPS, Q1 2026 earnings at $4.60 EPS, Q2 2026 earnings at $4.60 EPS, Q3 2026 earnings at $3.35 EPS, Q4 2026 earnings at $3.38 EPS, FY2027 earnings at $17.07 EPS, FY2028 earnings at $18.06 EPS and FY2029 earnings at $19.25 EPS.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biotechnology company reported $3.02 earnings per share for the quarter, missing the consensus estimate of $3.26 by ($0.24). The company had revenue of $2.43 billion for the quarter, compared to the consensus estimate of $2.25 billion. Biogen had a net margin of 15.07% and a return on equity of 14.03%. Biogen's quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.67 EPS.

Several other equities analysts have also weighed in on the stock. Hsbc Global Res lowered shares of Biogen from a "strong-buy" rating to a "hold" rating in a research report on Monday, April 28th. Piper Sandler restated a "neutral" rating and set a $115.00 price target on shares of Biogen in a research report on Thursday, June 12th. JPMorgan Chase & Co. reduced their price target on shares of Biogen from $185.00 to $175.00 and set a "neutral" rating for the company in a research report on Monday, May 5th. Canaccord Genuity Group reduced their price target on shares of Biogen from $265.00 to $220.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Finally, Royal Bank Of Canada set a $213.00 price target on shares of Biogen and gave the company an "outperform" rating in a research report on Wednesday, June 25th. Twenty investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat.com, Biogen currently has a consensus rating of "Hold" and a consensus price target of $188.48.

Biogen Stock Performance

BIIB traded down $3.70 during trading on Thursday, hitting $124.99. 1,524,786 shares of the company traded hands, compared to its average volume of 1,568,816. The firm has a market cap of $18.31 billion, a P/E ratio of 12.34, a price-to-earnings-growth ratio of 1.03 and a beta of 0.14. The stock's fifty day moving average is $129.04 and its 200 day moving average is $133.50. The company has a quick ratio of 1.01, a current ratio of 1.44 and a debt-to-equity ratio of 0.27. Biogen has a one year low of $110.04 and a one year high of $236.48.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Generali Investments CEE investicni spolecnost a.s. raised its position in Biogen by 43.2% during the second quarter. Generali Investments CEE investicni spolecnost a.s. now owns 38,755 shares of the biotechnology company's stock valued at $4,867,000 after purchasing an additional 11,695 shares in the last quarter. Greenleaf Trust raised its position in Biogen by 91.8% during the second quarter. Greenleaf Trust now owns 5,669 shares of the biotechnology company's stock valued at $712,000 after purchasing an additional 2,714 shares in the last quarter. Capital Investment Advisors LLC raised its position in Biogen by 5.4% during the second quarter. Capital Investment Advisors LLC now owns 2,164 shares of the biotechnology company's stock valued at $272,000 after purchasing an additional 111 shares in the last quarter. HB Wealth Management LLC raised its position in Biogen by 12.6% during the second quarter. HB Wealth Management LLC now owns 2,712 shares of the biotechnology company's stock valued at $341,000 after purchasing an additional 303 shares in the last quarter. Finally, Janney Montgomery Scott LLC raised its stake in shares of Biogen by 6.5% during the second quarter. Janney Montgomery Scott LLC now owns 19,099 shares of the biotechnology company's stock worth $2,399,000 after acquiring an additional 1,158 shares in the last quarter. Institutional investors own 87.93% of the company's stock.

Insider Activity at Biogen

In other news, insider Rachid Izzar sold 2,223 shares of Biogen stock in a transaction on Tuesday, July 8th. The shares were sold at an average price of $135.00, for a total transaction of $300,105.00. Following the completion of the sale, the insider directly owned 6,330 shares of the company's stock, valued at approximately $854,550. The trade was a 25.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.18% of the stock is owned by insiders.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.